Trial Sponsored by:



Trial Summary

PARADISE-MI:  Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI 

The purpose of this study was to evaluate the efficacy and safety of LCZ696 (sacubitril-valsartan) titrated to a target dose of 200 mg twice daily, compared to Ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-acute myocardial infarction (AMI) treatment, in reducing the occurrence of composite endpoint of cardiovascular death, heart failure (HF) hospitalisation and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of left ventricular systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.

A multi-centre, randomised, double-blind, active-controlled, parallel-group phase 3 study, PARADISE-MI demonstrated that sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident HF than Ramipril among patients with AMI.



  • Novartis Pharmaceuticals

Chief Investigator        

  • Professor Marc Pfeffer

Principal Investigator  

Trial Nurse

  • Ms Barbara Meyer      

Patient Recruitment

Recruitment status: Completed